Small molecule inhibitors targeting regulatory T cells for cancer treatment.

Cancer Immunotherapy Regulatory T cells Small molecules

Journal

European journal of immunology

ISSN: 1521-4141

Titre abrégé: Eur J Immunol

Pays: Germany

ID NLM: 1273201

Informations de publication

Date de publication:
08 Nov 2023

Historique:

revised: 03 11 2023

received: 30 06 2023

accepted: 07 11 2023

pubmed: 8 11 2023

medline: 8 11 2023

entrez: 8 11 2023

Statut: aheadofprint

Résumé

Regulatory T cells (Tregs) are important controllers of the immune system homeostasis by preventing disproportionate immune responses. In the context of cancer, Tregs contribute to tumor development by suppressing other immune cells in the tumor microenvironment (TME). Infiltration of Tregs in the TME has been associated with poor prognosis in cancer patients. Thus, understanding the mechanisms underlying Treg recruitment and suppressive functions is essential for developing cancer immunotherapies to boost antitumor immune responses. While antibody-based strategies targeting Tregs have shown promise, small molecule inhibitors offer distinct advantages, including oral bioavailability and the ability to penetrate the TME and target intracellular proteins. Here, we provide an overview of small molecule inhibitors that have demonstrated efficacy in modulating Tregs activity in cancer and highlight the need for phenotypic assays to characterize therapeutic compounds.

Identifiants

DOI: 10.1002/eji.202350448 PMID: 37937687

pubmed: 37937687

doi: 10.1002/eji.202350448

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Pagination

e2350448

Subventions

Organisme : Norwegian Centre for Clinical Cancer Research - MATRIX

ID : 328827

Organisme : European Union's Horizon 2020 Research and Innovation - Marie Skłodowska-Curie Actions

ID : 80113

Organisme : Norges Forskningsråd

ID : 315538

Organisme : Kreftforeningen

ID : 215850

Organisme : Helse Sør-Øst RHF

ID : 2020045

Organisme : Helse Sør-Øst RHF

ID : 2021082

Informations de copyright

Références

Hadis, U., Wahl, B., Schulz, O., Hardtke-Wolenski, M., Schippers, A., Wagner, N., Müller, W. et al., Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. Immunity 2011. 34: 237-246.

Samstein, R. M., Josefowicz, S. Z., Arvey, A., Treuting, P. M. and Rudensky, A. Y. Extrathymic generation of regulatory t cells in placental mammals mitigates maternal-fetal conflict. Cell 2012. 150: 29-38.

Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C. et al., Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009. 30: 899-911.

Tanaka, A. and Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Res 2017. 27: 109-118.

Ohue, Y. and Nishikawa, H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci 2019. 110: 2080-2089.

Shang, B., Liu, Y., Jiang, S. J. and Liu, Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci. Rep. 2015. 5: 1-9.

Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C. et al., Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 2009. 27: 186-192.

Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. E. H., Mosseri, V. et al., Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 2006. 12: 465-472.

Yoshioka, T., Miyamoto, M., Cho, Y., Ishikawa, K., Tsuchikawa, T., Kadoya, M., Li, L. et al., Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br. J. Cancer. 2008. 98: 1258-1263.

Zhang, X., Kelaria, S., Kerstetter, J. and Wang, J. The functional and prognostic implications of regulatory T cells in colorectal carcinoma. J. Gastrointest. Oncol. 2015. 6: 307-313.

Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y. et al., Two FOXP3 + CD4 + T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 2016. 22: 679-684.

Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S. et al., Anti-CCR4 mAb selectively depletes effector-Type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 2013. 110: 17945-17950.

Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfl, V., Biota, C. et al., Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009. 69: 2000-2009.

Ishida, T., Ishii, T., Inagaki, A., Yano, H., Komatsu, H., Iida, S., Inagaki, H. et al., Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006. 66: 5716-5722.

Ferenczi, K., Fuhlbrigge, R. C., Pinkus, J. L., Pinkus, G. S. and Kupper, T. S. Increased CCR4 expression in cutaneous T cell lymphoma. J. Invest. Dermatol. 2002. 119: 1405-1410.

De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P. et al., Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 2016. 45: 1135-1147.

Barsheshet, Y., Wildbaum, G., Levy, E., Vitenshtein, A., Akinseye, C., Griggs, J., Lira, S. A. et al., CCR8+FOXp3+ Treg cells as master drivers of immune regulation. Proc Natl Acad Sci USA 2017. 114: 6086-6091.

Loyher, P. L., Rochefort, J., Baudesson De Chanville, C., Hamon, P., Lescaille, G., Bertolus, C., Guillot-Delost, M. et al., CCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivity. Cancer Res 2016. 76: 6483-6494.

Ward, S. T., Li, K. K., Hepburn, E., Weston, C. J., Curbishley, S. M., Reynolds, G. M., Hejmadi, R. K. et al., The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br. J. Cancer. 2015. 112: 319-328.

Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L. P., Gimotty, P. A. et al., Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells. Nature 2011. 475: 226-230.

Ren, L., Yu, Y., Wang, L., Zhu, Z., Lu, R. and Yao, Z. Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer. Oncotarget 2016. 7.

Li, Q., Lu, J., Li, J., Zhang, B., Wu, Y. and Ying, T. Antibody-based cancer immunotherapy by targeting regulatory T cells. Front. Oncol. 2023. 3: 1-13.

Lipinski, C. A., Lombardo, F., Dominy, B. W. and Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001. 46: 3-26.

Rhee, P., Oh, D.-Y., Ryu, M. H., Hwang, J.-E., Cho, J., Zang, D. Y., Oh, S. C. et al., 658 A phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer. J Immunother Cancer 2022. 10: A688-A688.

Jackson, J. J., Ketcham, J. M., Younai, A., Abraham, B., Biannic, B., Beck, H. P., Bui, M. H. T. et al., Discovery of a potent and selective CCR4 antagonist that inhibits treg trafficking into the tumor microenvironment. J. Med. Chem. 2019. 62: 6190-6213.

Robles, O., Jackson, J. J., Marshall, L., Talay, O., Chian, D., Cutler, G., Diokno, R. et al., Novel piperidinyl-azetidines as potent and selective CCR4 antagonists elicit antitumor response as a single agent and in combination with checkpoint inhibitors. J. Med. Chem. 2020. 63: 8584-8607.

Marshall, L. A., Marubayashi, S., Jorapur, A., Jacobson, S., Zibinsky, M., Robles, O., Hu, D. X. et al., Tumors establish resistance to immunotherapy by regulating T reg recruitment via CCR4. J. Immunother. Cancer. 2020. 8

Le, D., Gutierrez, M. E., Saleh, M., Chen, E., Mallick, A. B., Pishvaian, M. J., Krauss, J. et al., Abstract CT124: a phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer. Cancer Res 2018. 78: CT124-CT124.

Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J. et al., Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 2009. 182: 1746-1755.

Wu, Y., Xi, J., Li, Y., Li, Z., Zhang, Y., Wang, J. and Fan, G. H. Discovery of a potent and selective CCR8 small molecular antagonist IPG7236 for the treatment of cancer. J. Med. Chem. 2023. 66: 4548-4564.

Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., Von Kriegsheim, A., Gómez-Cuadrado, L. et al., Nuclear FAK controls chemokine transcription, tregs, and evasion of anti-tumor immunity. Cell 2015. 163: 160-173.

Ozmadenci, D., Shankara Narayanan, J. S., Andrew, J., Ojalill, M., Barrie, A. M., Jiang, S., Iyer, S. et al., Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. Proc Natl Acad Sci USA 2022. 119: e2117065119.

Wei, Y., Wang, Y., Liu, N., Qi, R., Xu, Y., Li, K., Feng, Y. et al., A FAK inhibitor boosts anti-PD1 immunotherapy in a hepatocellular carcinoma mouse model. Front. Pharmacol. 2022. 12: 1-12.

Canel, M., Taggart, D., Sims, A. H., Lonergan, D. W., Waizenegger, I. C. and Serrels, A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. eLife 2020. 9.

Tanaka, A., Nishikawa, H., Noguchi, S., Sugiyama, D., Morikawa, H., Takeuchi, Y., Ha, D. et al., Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J. Exp. Med. 2020. 217.

Tanaka, A., Maeda, S., Nomura, T., Llamas-Covarrubias, M. A., Tanaka, S., Jin, L., Lim, E. L. et al., Construction of a T cell receptor signaling range for spontaneous development of autoimmune disease. J. Exp. Med. 2023. 220.

Najima, Y., Yoshida, C., Iriyama, N., Fujisawa, S., Wakita, H., Chiba, S., Okamoto, S. et al., Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-the final results of the D-first study. Leuk. Res. 2018. 66: 66-72.

Patton, D. T., Garden, O. A., Pearce, W. P., Clough, L. E., Monk, C. R., Leung, E., Rowan, W. C. et al., Cutting edge: the phosphoinositide 3-kinase p110δ is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 2006. 177: 6598-6602.

Ahmad, S., Abu-Eid, R., Shrimali, R., Webb, M., Verma, V., Doroodchi, A., Berrong, Z. et al., Differential PI3Kδ signaling in CD4+ T-cell subsets enables selective targeting of t regulatory cells to enhance cancer immunotherapy. Cancer Res 2017. 77: 1892-1904.

Chellappa, S., Kushekhar, K., Munthe, L. A., Tjønnfjord, G. E., Aandahl, E. M., Okkenhaug, K. and Taskén, K. The PI3K p110δ isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function. J. Immunol. 2019. 202: 1397-1405.

Eschweiler, S., Ramírez-Suástegui, C., Li, Y., King, E., Chudley, L., Thomas, J., Wood, O. et al., Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. Nature 2022. 605: 741-746.

Abu-Eid, R., Samara, R. N., Ozbun, L., Abdalla, M. Y., Berzofsky, J. A., Friedman, K. M., Mkrtichyan, M. et al., Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol. Res. 2014. 2: 1080-1089.

Gadi, D., Griffith, A., Wang, Z., Tyekucheva, S., Rai, V., Fernandes, S. M., Machado, J. H. et al., Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia. Br. J. Haematol. 2022. 197: 207-211.

Lampson, B. L., Kasar, S. N., Matos, T. R., Morgan, E. A., Rassenti, L., Davids, M. S., Fisher, D. C. et al., Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 2016. 128: 195-203.

Shin, N., Stubbs, M., Koblish, H., Yue, E. W., Soloviev, M., Douty, B., Wang, K. H. et al., Parsaclisib is a next-generation phosphoinositide 3-kinase δ inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell malignancy. J. Pharmacol. Exp. Ther. 2020. 374: 211-222.

Kalland, M. E., Oberprieler, N. G., Vang, T., Taskén, K. and Torgersen, K. M. T cell-signaling network analysis reveals distinct differences between CD28 and CD2 costimulation responses in various subsets and in the MAPK pathway between resting and activated regulatory T cells. J. Immunol. 2011. 187: 5233-5245.

Baumann, D., Hägele, T., Mochayedi, J., Drebant, J., Vent, C., Blobner, S., Noll, J. H. et al., Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy. Nat. Commun. 2020. 11.

Dushyanthen, S., Teo, Z. L., Caramia, F., Savas, P., Mintoff, C. P., Virassamy, B., Henderson, M. A. et al., Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nat. Commun. 2017. 8: 1-18.

Kolb, R., De, U., Khan, S., Luo, Y., Kim, M. C., Yu, H., Wu, C. et al., Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat. Commun. 2021. 12: 1-9.

Békés, M., Langley, D. R. and Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 2022. 21: 181-200.

Wang, Y., Huang, T., Gu, J. and Lu, L. Targeting the metabolism of tumor-infiltrating regulatory T cells. Trends Immunol 2023. 44: 598-612.

Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T. et al., Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 2022. 40: 201-218.e9.

Lal, G. and Bromberg, J. S. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009. 114: 3727.

Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P., Shrikant, P. et al., Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One 2012. 7.

Briere, D., Sudhakar, N., Woods, D. M., Hallin, J., Engstrom, L. D., Aranda, R., Chiang, H. et al., The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol. Immunother. 2018. 67: 381-392.

Wang, D., Quiros, J., Mahuron, K., Pai, C. C., Ranzani, V., Young, A., Silveria, S. et al., Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep 2018. 23: 3262-3274.

Liu, Y., Wang, L., Predina, J., Han, R., Beier, U. H., Wang, L. C. S., Kapoor, V. et al., Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity. Nat. Med. 2013. 19: 1173-1177.

Fontenot, J. D., Gavin, M. A. and Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. J. Immunol. 2017. 198: 986-992.

Hori, S., Nomura, T. and Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003. 299: 1057-1061.

Khattri, R., Cox, T., Yasayko, S. A. and Ramsdell, F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 2003. 4: 337-342.

Revenko, A., Carnevalli, L. S., Sinclair, C., Johnson, B., Peter, A., Taylor, M., Hettrick, L. et al., Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. J. Immunother. Cancer. 2022. 10.

Hawleya, K. M., Eclova, R. J., Schnorenberga, M. R., Tianc, Y., Shaha, R. N., Thomas-Toth, A. T., Feffermana, M. et al., Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function. Proc. Natl. Acad. Sci 2017. 120: 2017.

Wang, Y., Zhang, Y., Su, S., Tamukong, P., Murali, R. and Kim, H. L. Stimulation of antitumor immunity by FoxP3-targeting PROTAC. Biomed. Pharmacother. 2023. 163: 114871.

Ding, M., Brengdahl, J., Lindqvist, M., Gehrmann, U., Ericson, E., Von Berg, S., Ripa, L. et al., A phenotypic screening approach using human Treg cells identified regulators of Forkhead box p3 expression. ACS Chem. Biol. 2019. 14: 543-553.

Mao, R., Liu, H., Yi, B., Purohit, S., Kuczma, M., Kraj, P. and She, J. X. Cell-based high throughput screening identified a novel compound that promotes regulatory T cells and prevents autoimmune colitis. Biochem. Pharmacol. 2019. 169: 113618.

Joslin, J., Gilligan, J., Anderson, P., Garcia, C., Sharif, O., Hampton, J., Cohen, S. et al., A fully automated high-throughput flow cytometry screening system enabling phenotypic drug discovery. SLAS Discov 2018. 23: 697-707.

Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W. et al., Interferon-γ drives Treg fragility to promote anti-tumor immunity. Cell 2017. 169: 1130-1141.e11

Mao, R., Xiao, W., Liu, H., Chen, B., Yi, B., Kraj, P. and She, J. X. Systematic evaluation of 640 FDA drugs for their effect on CD4 +Foxp3+ regulatory T cells using a novel cell-based high throughput screening assay. Biochem. Pharmacol. 2013. 85: 1513-1524.

Ziegler, S. F. FOXP3: of mice and men. Annu. Rev. Immunol. 2006. 24: 209-226.

Sicoli, D., Jiao, X., Ju, X., Velasco-Velazquez, M., Ertel, A., Addya, S., Li, Z. et al., CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines. Cancer Res 2014. 74: 7103-7114.

Halvorsen, E. C., Hamilton, M. J., Young, A., Wadsworth, B. J., LePard, N. E., Lee, H. N., Firmino, N. et al., Maraviroc decreases CCL8-mediated migration of CCR5+ regulatory T cells and reduces metastatic tumor growth in the lungs. Oncoimmunology 2016. 5: 1-15.

Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M. et al., Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22: 851-860. 2016.

Lauder, S. N., Smart, K., Bart, V. M. T., Pires, A., Scott, J., Milutinovic, S., Godkin, A. et al., Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion. Br. J. Cancer. 2022. 127: 1595-1602.

Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H. et al., Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014. 510: 407-411.

Fukuhara, N., Suehiro, Y., Kato, H., Kusumoto, S., Coronado, C., Rappold, E., Zhao, W. et al., Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): a phase Ib study. Cancer Sci 2022. 113: 1702-1711.

Forero-Torres, A., Ramchandren, R., Yacoub, A., Wertheim, M. S., Edenfield, W. J., Caimi, P., Gutierrez, M. et al., Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood 2019. 133: 1742-1752.

Coleman, M., Belada, D., Casasnovas, R. O., Gressin, R., Lee, H. P., Mehta, A., Munoz, J. et al., Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leuk. Lymphoma. 2021. 62: 368-376.

Sommakia, S., Matsumura, Y., Allred, C., Pathi, S., Tyagi, E., Foulks, J., Siddiqui, A. et al., The PKM2 activator and molecular glue TP-1454 modulates tumor-immune responses by destabilizing T-regulatory cells. Eur. J. Cancer. 2022. 174: S47.

Rao, A., Taylor, J. L., Chi-Sabins, N., Kawabe, M., Gooding, W. E. and Storkus, W. J. Combination therapy with hsp90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Res 2012. 72: 3196-3206.

Leone, R. D., Sun, I. M., Oh, M. H., Sun, I. H., Wen, J., Englert, J. and Powell, J. D. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunol. Immunother. 2018. 67: 1271-1284.

Ma, S. R., Deng, W. W., Liu, J. F., Mao, L., Yu, G. T., Bu, L. L., Kulkarni, A. B. et al., Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol. Cancer. 2017. 16.

Zhang, C., He, S., Zeng, Z., Cheng, P. and Pu, K. Smart nano-PROTACs reprogram tumor microenvironment for activatable photo-metabolic cancer immunotherapy. Angew. Chemie - Int. Ed. 2022. 61.

Bonazzi, S., D'Hennezel, E., Beckwith, R. E. J., Xu, L., Fazal, A., Magracheva, A., Ramesh, R. et al., Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. Cell Chem. Biol. 2023. 30: 235-247.e12

Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E. et al., Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007. 56: 641-648.

Scurr, M., Pembroke, T., Bloom, A., Roberts, D., Thomson, A., Smart, K., Bridgeman, H. et al., Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin. Cancer Res. 2017. 23: 6771-6780.

Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A. and Ullenhag, G. Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/Treg ratio in patients with pancreatic cancer. J. Transl. Med. 2016. 14: 1-12.

Hira, S. K., Rej, A., Paladhi, A., Singh, R., Saha, J., Mondal, I., Bhattacharyya, S. et al., Galunisertib drives Treg fragility and promotes dendritic cell-mediated immunity against experimental lymphoma. iScience 2020. 23.